中文版 | English
Title

细胞间黏附分子-1及肿瘤坏死因子受体1在糖尿病肾病患者中的表达水平及其诊断价值

Author
Publication Years
2022
DOI
Source Title
ISSN
1004-0412
Volume43Issue:5Pages:1247-1249
Abstract
目的:探讨细胞间黏附分子-1(sICAM-1)及肿瘤坏死因子受体1(TNFR1)在糖尿病肾病(DN)患者中的表达水平及其诊断价值.方法:选取2020年1月~2021年6月糖尿病患者153例为观察组,观察组按Mogensen分期分为Ⅰ期、Ⅱ期、Ⅲ期、Ⅳ期、Ⅴ期共五组;按尿白蛋白排泄率(UAER)分为1型糖尿病组、1型糖尿病早期肾病组、2型糖尿病组、2型糖尿病早期肾病组四组.随机选取健康体验者30例为对照组,采用双抗夹心酶联免疫吸附法(ELISA)测定血清中sICAM-1与TNFR1水平,分析其在DN患者中的表达水平及诊断价值.结果:与对照组相比,Ⅰ期、Ⅱ期、Ⅲ期、Ⅳ期、Ⅴ期血清中sICAM-1与TNFR1含量明显升高,差异有统计学意义(P<0.05);与对照组相比,1型糖尿病组、1型糖尿病早期肾病组、2型糖尿病组、2型糖尿病早期肾病组血清中sICAM-1与TNFR1含量明显升高,差异有统计学意义(P<0.05),且1型糖尿病早期肾病组血清中sICAM-1与TNFR1含量明显高于1型糖尿病组,差异有统计学意义(P<0.05),2型糖尿病早期肾病组血清中sICAM-1与TNFR1含量明显高于2型糖尿病组,差异有统计学意义(P<0.05);血清sICAM-1检测的AUC为0.828,血清TNFR1检测为0.820,两者联合为0.919.结论:sICAM-1及TNFR1在DN患者中含量显著升高,sICAM-1和TNFR1检测具有较高的诊断价值,且二者联合检测价值更高,可用于检测DN.
Keywords
URL[Source Record]
Language
Chinese
SUSTech Authorship
Others
Data Source
WanFang
WanFangID
jilinyx202205030
Citation statistics
Cited Times [WOS]:0
Document TypeJournal Article
Identifierhttp://kc.sustech.edu.cn/handle/2SGJ60CL/401840
DepartmentSouthern University of Science and Technology Hospital
Affiliation
南方科技大学医院重症医学科,广东 深圳 518000
Recommended Citation
GB/T 7714
熊敏,潘勇军,苗新宇. 细胞间黏附分子-1及肿瘤坏死因子受体1在糖尿病肾病患者中的表达水平及其诊断价值[J]. 吉林医学,2022,43(5):1247-1249.
APA
熊敏,潘勇军,&苗新宇.(2022).细胞间黏附分子-1及肿瘤坏死因子受体1在糖尿病肾病患者中的表达水平及其诊断价值.吉林医学,43(5),1247-1249.
MLA
熊敏,et al."细胞间黏附分子-1及肿瘤坏死因子受体1在糖尿病肾病患者中的表达水平及其诊断价值".吉林医学 43.5(2022):1247-1249.
Files in This Item:
There are no files associated with this item.
Related Services
Fulltext link
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Export to Excel
Export to Csv
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[熊敏]'s Articles
[潘勇军]'s Articles
[苗新宇]'s Articles
Baidu Scholar
Similar articles in Baidu Scholar
[熊敏]'s Articles
[潘勇军]'s Articles
[苗新宇]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[熊敏]'s Articles
[潘勇军]'s Articles
[苗新宇]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.